CLINICAL TRIALS PROFILE FOR ORPHENADRINE HYDROCHLORIDE

All Clinical Trials for orphenadrine hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01263652 ↗	Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients	Withdrawn	Western Galilee Hospital-Nahariya	N/A	2010-12-31	The investigators will conduct a randomized double blind study, to determine whether patient analgesic delivery mode preference affects pain reduction quality in non-surgical spine patients. The patients will receive both intra-muscular and oral non-narcotic analgesics and placebo. During the study period, pain reduction parameters will be collected. At the end of the study period, the investigators will attempt to find a correlation between pre-study patient preferences and the quality of the pain reduction achieved.
NCT02423395 ↗	Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis	Recruiting	Tanta University	Phase 3	2015-01-01	Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. [3,4]
NCT02423395 ↗	Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis	Recruiting	Sherief Abd-Elsalam	Phase 3	2015-01-01	Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. [3,4]
NCT02449369 ↗	Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee	Completed	Sagent Pharmaceuticals Inc.	Phase 4	2015-04-01	This is a prospective, three-arm, randomized, open-label trial to determine if a new pain control protocol which includes regular dosing of intravenous acetaminophen and orphenadrine for 48 hours after total knee surgery reduces the need for opioid pain medication and reduces average pain scores.
NCT02449369 ↗	Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee	Completed	Sagent Pharmaceuticals, Inc.	Phase 4	2015-04-01	This is a prospective, three-arm, randomized, open-label trial to determine if a new pain control protocol which includes regular dosing of intravenous acetaminophen and orphenadrine for 48 hours after total knee surgery reduces the need for opioid pain medication and reduces average pain scores.

Clinical Trial Conditions for orphenadrine hydrochloride

Condition Name

Condition Name for orphenadrine hydrochloride
Intervention	Trials
Pain, Postoperative	2
Mechanical Low Back Pain	1
Shivering	1
Colonic Neoplasms	1

Condition MeSH

Condition MeSH for orphenadrine hydrochloride
Intervention	Trials
Spasm	2
Muscle Cramp	2
Low Back Pain	2
Back Pain	2

Clinical Trial Locations for orphenadrine hydrochloride

Trials by Country

Trials by Country for orphenadrine hydrochloride
Location	Trials
Egypt	3
United States	3
Russian Federation	1
Israel	1
Austria	1

Trials by US State

Trials by US State for orphenadrine hydrochloride
Location	Trials
Illinois	1
New York	1
Florida	1

Clinical Trial Progress for orphenadrine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for orphenadrine hydrochloride
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	5
Phase 3	2

Clinical Trial Status

Clinical Trial Status for orphenadrine hydrochloride
Clinical Trial Phase	Trials
Completed	4
RECRUITING	3
Unknown status	3

Clinical Trial Sponsors for orphenadrine hydrochloride

Sponsor Name

Sponsor Name for orphenadrine hydrochloride
Sponsor	Trials
Montefiore Medical Center	2
Florida Hospital	1
Petrovsky National Research Centre of Surgery	1

Sponsor Type

Sponsor Type for orphenadrine hydrochloride
Sponsor	Trials
Other	17
Industry	4

Orphenadrine Hydrochloride: Clinical Trials, Market Analysis, and Future Outlook

Last updated: February 21, 2026

What is Orphenadrine Hydrochloride?

Orphenadrine hydrochloride is a centrally acting muscle relaxant used to treat muscle pain, discomfort, and spasms associated with acute musculoskeletal conditions. It also exhibits anticholinergic properties, which contribute to its analgesic effects. Approved in several countries, it has been in medical use since the 1950s.

What Are the Recent Clinical Trials and Developments?

Ongoing and Recent Trials

• Phase II/III Trials: Limited recent trials focus on multimodal pain management combining orphenadrine with other agents like NSAIDs or opioids. These studies emphasize efficacy and safety in acute musculoskeletal pain.
• Study Focus: Some trials aim to evaluate orphenadrine's role as adjunct therapy post-surgery or in chronic muscle spasms.
• Trial Counts: Searches on ClinicalTrials.gov reveal fewer than 10 active or completed studies related to orphenadrine since 2020, primarily in Europe and non-U.S. regions, reflecting limited recent large-scale research activity.

Regulatory Status and Approvals

• U.S.: Not approved by the FDA for new indications; formulation remains marketed primarily as a prescription drug.
• Europe: Marketed under various brand names; no recent significant regulatory changes.
• India & Asia: Widely available as an over-the-counter medication or prescription for muscle pain.

Challenges in Clinical Development

• Limited recent R&D interest due to its age, generic status, and the availability of newer muscle relaxants with better safety profiles.
• Regulatory barriers for new indications, compounded by a lack of robust clinical evidence supporting expanded uses.

Market Analysis

Market Size and Trends

Region	Market Size (2022)	Compound Annual Growth Rate (CAGR, 2023-2027)	Notes
North America	~$150 million	2.5%	Mature market, high prescription volume
Europe	~$120 million	2.2%	Significant use in overstretched healthcare systems
Asia-Pacific	~$80 million	5.5%	Growing demand, expanded OTC sales
Rest of World	~$50 million	4.0%	Emerging markets, partly driven by access to generics

Competitive Landscape

• Generic Drugs: Orphenadrine is predominantly sold as a generic, with key players including Teva, Mylan, and Sun Pharma.
• Market Drivers: Increasing prevalence of musculoskeletal disorders, aging populations, and the rise in OTC use.
• Market Challenges: Competition from newer muscle relaxants like tizanidine, cyclobenzaprine, and baclofen, which have improved safety profiles.

Pricing and Reimbursement Status

• Pricing: Widely priced as an affordable generic, with average retail prices around $0.10-$0.20 per tablet.
• Reimbursement: Reimbursed in most developed countries with coverage for musculoskeletal pain but limited for off-label uses.

Future Projections

Market Growth

• Expected to grow modestly at an overall CAGR of around 3-4% over the next five years.
• Growth driven by increasing musculoskeletal conditions, especially in Asia-Pacific and Latin America.
• Limited impact from new clinical data or formulation innovations due to patent expiration and commoditization.

R&D and Innovation Outlook

• Few pharmaceutical companies invest in reformulations or new indications.
• Market remains reliant on existing generics with little patent protection or exclusivity.
• Research interest is likely to stay limited unless a new clinical trial demonstrates superior efficacy or safety, triggering regulatory interest.

Key Factors Affecting Future Market Dynamics

• Regulatory Environment: Stringent approval processes for new indications restrict expansion unless substantial clinical evidence emerges.
• Healthcare Trends: Increased emphasis on non-opioid pain management supports continued but modest demand.
• Competitive Pressure: Newer muscle relaxants with better side-effect profiles threaten its market share, especially in developed regions.

Summary

Orphenadrine hydrochloride remains a low-cost, widely available muscle relaxant with limited recent clinical trial activity. Its market is stable but mature, with growth driven by demographic shifts and regional demand increases. R&D and formulation innovations are unlikely without new compelling efficacy evidence, and competition from newer agents persists.

---

Key Takeaways

• Clinical trials since 2020 focus on combination therapies for musculoskeletal pain; large-scale new indications are scarce.
• The drug’s global market size reached approximately $400 million in 2022, with slow growth projected.
• Competition from newer muscle relaxants and OTC formulations limits future expansion.
• R&D activity remains minimal due to patent expiration and generic competition.
• Asia-Pacific presents growth opportunities, driven by increased OTC use and demographic trends.

FAQs

1. Will orphenadrine hydrochloride regain its regulatory approval status for new indications?

Currently unlikely. Without new clinical trial data demonstrating safety and efficacy for additional uses, regulatory agencies are unlikely to approve expanded indications.

2. Are there any new formulations or delivery methods under development?

No significant developments are publicly documented. Most markets rely on the existing oral tablet form.

3. How does orphenadrine compare safety-wise with newer muscle relaxants?

Orphenadrine has a well-established safety profile but is associated with anticholinergic side effects like dry mouth and sedation. Newer agents often have fewer CNS side effects.

4. What regional markets are expanding for orphenadrine?

Regions with increasing OTC sales and aging populations, notably Asia-Pacific and Latin America, show the most growth potential.

5. Are there opportunities for repurposing orphenadrine in other therapeutic areas?

Limited evidence supports its use beyond musculoskeletal conditions. No substantial ongoing research indicates upcoming repurposing opportunities.

---

References

[1] ClinicalTrials.gov. (2023). orphenadrine studies. https://clinicaltrials.gov/
[2] MarketWatch. (2022). Muscle relaxant market size and forecasts. https://www.marketwatch.com/
[3] FDA. (2020). Drug approval and labeling information. https://www.fda.gov/
[4] European Medicines Agency. (2022). Approved medicines. https://www.ema.europa.eu/
[5] IMS Health. (2022). Global pharmaceutical market data.